Metformin prevents the development of atrial fibrillation

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The practice of repurposing drugs intended to treat one nosology as a means to treat new diseases or conditions is currently being considered. Thus, metformin, as a biguanide derivative (dimethylbiguanide), intended as a hypoglycemic agent for the treatment of patients with type 2 diabetes mellitus, shows effectiveness in the prevention and treatment of AF. A lot of data has accumulated indicating various effects of metformin, in addition to the hypoglycemic effect, in particular cardioprotective effects. Cardioprotection is based on the activation of 5’-adenosine monophosphate-activated protein kinase (AMPK), which helps maintain/generate ATP, prevent necrosis/apoptosis, reduce oxidative stress and inflammation. Experimental studies have shown that metformin prevents unfavorable structural and electrical remodeling of the atria, preventing the development of AF. Several cohort studies have been conducted in which patients treated with metformin showed a reduced risk of developing episodes of AF and increased survival, and when compared with other hypoglycemic drugs (sulfonylurea derivatives, thiazolidinedione, α-glucosidase inhibitors, dipeptidyl peptidase inhibitors, glucagon-like peptide-1 receptor agonists) it was in the metformin group that a significantly lower risk of developing AF was observed. The results of transcriptomic analysis for metformin provided data demonstrating the drug as a candidate for repurposing the drug for the treatment of AF. At this stage, further studies of appropriate quality to clarify the beneficial effects of metformin on cardiac arrhythmias are of paramount importance.

Full Text

Restricted Access

About the authors

M. V. Leonova

Interregional Public Organization of the Association of Clinical Pharmacologists (Moscow branch)

Author for correspondence.
Email: anti23@mail.ru
ORCID iD: 0000-0001-8228-1114
SPIN-code: 3281-7884

Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Natural Sciences

Russian Federation, Moscow

References

  1. Rojas L.B., Gomes M.B. Metformin: an old but still the best treatment for type 2 diabetes. Diab Metab Syndr. 2013;5(1):6. doi: 10.1186/1758-5996-5-6.
  2. Rena G., Lang C.C. Repurposing metformin for cardiovascular disease. Circulation. 2018;137(5):422–24. doi: 10.1161/CIRCULATIONAHA.117.031735.
  3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65.
  4. Lamanna C., Monami M., Marchionni N., Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diab Obes Metab. 2011;13(3):221–28. doi: 10.1111/j.1463-1326.2010.01349.x.
  5. Han Y., Xie H., Liu Y., et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diab. 2019;18(1):96. doi: 10.1186/s12933-019-0900-7.
  6. Varjabedian L., Bourji M., Pourafkari L., Nader N.D. Cardioprotection by metformin: beneficial effects beyond glucose reduction. Am J Cardiovasc Drugs. 2018;18(3):181–93. doi: 10.1007/s40256-018-0266-3.
  7. Driver C., Bamitale K.D.S., Kazi A., et al. Cardioprotective Effects of Metformin. J Cardiovasc Pharmacol. 2018;72(2):121–27. doi: 10.1097/FJC.0000000000000599.
  8. Nantsupawat T., Wongcharoen W., Chattipakorn S.C., et al. Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient. Cardiovasc Diab. 2020;19:198. doi: 10.1186/s12933-020-01176-4.
  9. Hindricks G., Potpara T., Dagres N., et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. doi: 10.1093/eurheartj/ehaa612.
  10. Wang A., Green J.B., Halperin J.L., Piccini J.P.Sr. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J Am Coll Cardiol. 2019;74(8):1107–15. doi: 10.1016/j.jacc.2019.07.020.
  11. Chan Y.H., Chang G.J., Lai Y.J., et al. Atrial fibrillation and its arrhythmogenesis associated with insulin resistance. Cardiovasc Diab. 2019;18(1):125. doi: 10.1186/s12933-019-0928-8.
  12. Casaclang-Verzosa G., Gersh B.J., Tsang T.S. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol. 2008;51(1):1–11. doi: 10.1016/j.jacc.2007.09.026.
  13. Li B., Po S.S., Zhang B., et al. Metformin regulates adiponectin signalling in epicardial adipose tissue and reduces atrial fibrillation vulnerability. J Cell Mol Med. 2020;24(14):7751–66. doi: 10.1111/jcmm.15407.
  14. Fu X., Pan Y., Cao Q., et al. Metformin restores electrophysiology of small conductance calcium-activated potassium channels in the atrium of GK diabetic rats. BMC. Cardiovasc Disord. 2018;18(1):63. doi: 10.1186/s12872-018-0805-5.
  15. Burla A.K., Lobato N.S., Fortes Z.B., et al. Cardiac fibrosis and vascular remodeling are attenuated by metformin in obese rats. Int J Cardiol. 2013;165(3):483–87. doi: 10.1016/j.ijcard.2011.09.012.
  16. Chang S.H., Wu L.S., Chiou M.J., et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diab. 2014;13:123. doi: 10.1186/s12933-014-0123-x.
  17. Liou Y.S., Yang F.Y., Chen H.Y., Jong G.P. Antihyperglycemic drugs use and new-onset atrial fibrillation: a population-based nested case control study. PLoS One. 2018;13(8):e0197245. doi: 10.1371/journal.pone.0197245.
  18. Ostropolets A., Elias P.A., Reyes M.V., et al. Metformin Is associated with a lower risk of atrial fibrillation and ventricular arrhythmias compared with sulfonylureas: an observational study. Circ Arrhythm Electrophysiol. 2021;14(3):e009115. doi: 10.1161/CIRCEP.120.009115.
  19. Lal J.C., Mao C., Zhou Y., et al. Transcriptomics-based network medicine approach identifies metformin as a repurposable drug for atrial fibrillation. Cell Rep Med. 2022;3(10):100749. doi: 10.1016/j.xcrm.2022.100749.
  20. Metformin for Atrial Fibrillarion Trial (MAFT). ClinicalTrials.gov Identifier: NCT05878535. URL: https://classic.clinicaltrials.gov/ct2/show/NCT05878535.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Kaplan-Meier curves of the incidence of FP-free survival in a population of patients with DM [16]

Download (67KB)
Indexing metadata
3. Fig. 2. Relative risk (RR) of first-onset FP on the background of different groups of hypoglycemic drugs [17]

Download (97KB)
Indexing metadata
4. Fig. 3. Comparison of the frequency of episodes of first-onset PD on the background of therapy with metformin and other groups of hypoglycemic drugs [18]

Download (94KB)
Indexing metadata
5. Fig. 4. Comparison of the frequency of episodes of first-onset PD on the background of therapy with metformin and hypoglycemic drugs of other groups [19]

Download (97KB)
Indexing metadata

Copyright (c) 2024 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies